RxDoctor Payments Data

Scott Gold, MD

Neurology · Melbourne, FLNPI 1578522058

Payments from drug & device makers

$189,104in general payments, 2019–2025

Across 781 payments — averaging $242.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$50K
  • EMD Serono, Inc.$43K
  • Biogen$40K
  • Genentech USA, Inc.$26K
  • E.r. Squibb & Sons, L.L.C.$11K
  • Bristol Myers Squibb$8K
  • plus $11K from 45 others

What the payments were for

  • Consulting fees$27,97115%
  • Speaking & faculty fees$134,28671%
  • Travel & lodging$8,1824%
  • Food & beverage$18,28310%
  • Education$3820%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$189,104 in reported general payments places this provider in the 85th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$62,818
Medicare patients
239
Services billed
757

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab53$571,607
AubagioTeriflunomide39$425,552
Teriflunomide33$126,247
CopaxoneGlatiramer Acetate15$109,796
GlatopaGlatiramer Acetate19$91,124
Dalfampridine ErDalfampridine43$77,704
Gamunex-CImmune Globul G/Gly/Iga Avg 4618$54,734
Glatiramer Acetate15$42,680
Dimethyl Fumarate28$39,155
NeuproRotigotine11$16,589
DilantinPhenytoin Sodium Extended23$7,587
Gabapentin190$5,186
Carbamazepine ErCarbamazepine28$5,068
Baclofen159$4,959
DayvigoLemborexant12$3,701

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SanofiAubagio$50,264$425,55239 claims
Teva Pharmaceuticals USA, Inc.Copaxone$355$109,79615 claims
Grifols USA, LLCGamunex-C$49$54,73418 claims
UCB, Inc.Neupro$215$16,58911 claims
Eisai Inc.Dayvigo$188$3,70112 claims
Almatica Pharma LLCSertraline Hcl$39$97733 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,434 neurology providers in Florida.

Other neurology in Melbourne

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →